Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Shares Bought by Amundi

Amundi boosted its holdings in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) by 10,967.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 329,582 shares of the company’s stock after buying an additional 326,604 shares during the period. Amundi owned approximately 0.26% of Apellis Pharmaceuticals worth $10,876,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently added to or reduced their stakes in the company. True Wealth Design LLC acquired a new position in shares of Apellis Pharmaceuticals in the third quarter valued at about $27,000. Wolverine Asset Management LLC acquired a new position in shares of Apellis Pharmaceuticals in the third quarter valued at about $27,000. KBC Group NV increased its holdings in shares of Apellis Pharmaceuticals by 34.8% in the third quarter. KBC Group NV now owns 2,632 shares of the company’s stock valued at $76,000 after purchasing an additional 679 shares during the period. US Bancorp DE increased its holdings in shares of Apellis Pharmaceuticals by 70.0% in the fourth quarter. US Bancorp DE now owns 3,223 shares of the company’s stock valued at $103,000 after purchasing an additional 1,327 shares during the period. Finally, XTX Topco Ltd acquired a new position in shares of Apellis Pharmaceuticals in the third quarter valued at about $206,000. 96.29% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Apellis Pharmaceuticals

In related news, CFO Timothy Eugene Sullivan sold 2,170 shares of Apellis Pharmaceuticals stock in a transaction that occurred on Monday, January 13th. The stock was sold at an average price of $28.70, for a total transaction of $62,279.00. Following the transaction, the chief financial officer now owns 88,100 shares in the company, valued at approximately $2,528,470. This trade represents a 2.40 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Caroline Baumal sold 2,816 shares of Apellis Pharmaceuticals stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $33.81, for a total value of $95,208.96. Following the transaction, the insider now owns 55,560 shares in the company, valued at approximately $1,878,483.60. The trade was a 4.82 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 65,934 shares of company stock valued at $1,950,261 over the last ninety days. Insiders own 6.80% of the company’s stock.

Wall Street Analyst Weigh In

APLS has been the topic of a number of research reports. The Goldman Sachs Group cut their price objective on Apellis Pharmaceuticals from $36.00 to $32.00 and set a “neutral” rating on the stock in a report on Monday, March 3rd. Royal Bank of Canada lowered their target price on Apellis Pharmaceuticals from $26.00 to $25.00 and set a “sector perform” rating on the stock in a research note on Monday, March 3rd. Morgan Stanley began coverage on Apellis Pharmaceuticals in a research note on Thursday, November 21st. They issued an “equal weight” rating and a $31.00 target price on the stock. JPMorgan Chase & Co. upped their target price on Apellis Pharmaceuticals from $50.00 to $54.00 and gave the stock an “overweight” rating in a research note on Tuesday, March 4th. Finally, HC Wainwright restated a “buy” rating and issued a $57.00 target price on shares of Apellis Pharmaceuticals in a research note on Monday, March 3rd. Eight investment analysts have rated the stock with a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $45.53.

Apellis Pharmaceuticals Stock Performance

Shares of NASDAQ:APLS opened at $24.66 on Friday. The company has a debt-to-equity ratio of 1.91, a current ratio of 4.36 and a quick ratio of 3.73. The business’s 50 day moving average price is $28.33 and its 200-day moving average price is $30.62. The firm has a market capitalization of $3.10 billion, a PE ratio of -12.15 and a beta of 0.92. Apellis Pharmaceuticals, Inc. has a 1 year low of $23.77 and a 1 year high of $59.91.

Apellis Pharmaceuticals (NASDAQ:APLS) last issued its quarterly earnings results on Friday, February 28th. The company reported ($0.29) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.37) by $0.08. The firm had revenue of $212.50 million for the quarter, compared to analyst estimates of $197.92 million. Apellis Pharmaceuticals had a negative return on equity of 103.11% and a negative net margin of 34.97%. The business’s revenue was up 45.2% on a year-over-year basis. During the same period in the previous year, the company posted ($0.73) earnings per share. As a group, equities research analysts expect that Apellis Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

Apellis Pharmaceuticals Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).